Morphocell Technologies announced a $50 million Series A financing extension — a $10 million add‑on to its earlier $40 million close — led by Investissement Québec with participation from CDP Venture Capital and prior investors. The Montreal‑area company said the proceeds lengthen its runway to more than three years and will accelerate development, manufacturing and preclinical work for next‑generation tissue therapeutics targeting liver disease. Morphocell described progress across discovery, cell manufacturing and vertical integration since its initial raise in 2024. The company now employs teams in Canada and the U.S., and the new capital aims to support GMP manufacturing scale‑up and IND‑enabling studies. Institutional backers framed the investment as a validation of Quebec‑based life‑science growth and the commercial potential of organ‑replacement tissue platforms. The extension reflects investor appetite for regenerative‑medicine plays that combine cell therapy, engineered tissues and in‑house manufacturing to address organ shortages and chronic organ failure.